Zobrazeno 1 - 10
of 44
pro vyhledávání: '"Thomas Felzmann"'
Autor:
Friedrich Erhart, Johanna Buchroithner, René Reitermaier, Katrin Fischhuber, Simone Klingenbrunner, Ido Sloma, Dror Hibsh, Renana Kozol, Sol Efroni, Gerda Ricken, Adelheid Wöhrer, Christine Haberler, Johannes Hainfellner, Günther Krumpl, Thomas Felzmann, Alexander M. Dohnal, Christine Marosi, Carmen Visus
Publikováno v:
Acta Neuropathologica Communications, Vol 6, Iss 1, Pp 1-14 (2018)
Abstract Audencel is a dendritic cell (DC)-based cellular cancer immunotherapy against glioblastoma multiforme (GBM). It is characterized by loading of DCs with autologous whole tumor lysate and in vitro maturation via “danger signals”. The recen
Externí odkaz:
https://doaj.org/article/31567993947f492daafe23f1e64695ff
Autor:
Romana Luger, Sneha Valookaran, Natalie Knapp, Caterina Vizzardelli, Alexander M Dohnal, Thomas Felzmann
Publikováno v:
PLoS ONE, Vol 8, Iss 2, p e54879 (2013)
The dendritic cell (DC) coordinates innate and adaptive immunity to fight infections and cancer. Our observations reveal that DCs exposed to the microbial danger signal lipopolysaccharide (LPS) in the presence of interferon-γ (IFN-γ) acquire a cont
Externí odkaz:
https://doaj.org/article/61c1b7c728ef4864aa29b4a006f307ab
Autor:
Katrin Fischhuber, Daniela Lötsch, Walter Berger, Alexander M. Dohnal, Fernando J. Sialana, Gert Lubec, Bernadette Blauensteiner, Friedrich Erhart, Simone Klingenbrunner, Thomas Felzmann, Angela Halfmann, Tamara Weiss, René Reitermaier, Carmen Visus, Sabine Spiegl-Kreinecker
Publikováno v:
Cytotherapy. 21:643-658
Background Glioblastoma is the most aggressive type of brain cancer. Dendritic cell (DC)-based immunotherapy against glioblastoma depends on the effectiveness of loaded antigens. Sphere-inducing culture conditions are being studied by many as a poten
Autor:
Johanna Heugenhauser, Malik Galijasevic, Stephanie Mangesius, Georg Goebel, Johanna Buchroithner, Friedrich Erhart, Josef Pichler, Georg Widhalm, Günther Stockhammer, Sarah Iglseder, Christian F. Freyschlag, Stefan Oberndorfer, Karin Bordihn, Gord von Campe, Thomas Czech, Birgit Surböck, Tadeja Urbanic Purkart, Christine Marosi, Thomas Felzmann, Martha Nowosielski
Publikováno v:
Cancers; Volume 14; Issue 6; Pages: 1579
Introduction: In this post hoc analysis we compared various response-assessment criteria in newly diagnosed glioblastoma (GB) patients treated with tumor lysate-charged autologous dendritic cells (Audencel) and determined the differences in predictio
Autor:
Friedrich Erhart, Simone Klingenbrunner, Hannes Hahne, Adelheid Wöhrer, Sabine Spiegl-Kreinecker, Johanna Buchroithner, Walter Berger, Matthias Hackl, Gerda Ricken, René Reitermaier, Carmen Visus, Katrin Fischhuber, Daniela Lötsch, Christine Marosi, Chen Meng, Johannes A. Hainfellner, Georg Widhalm, Thomas Felzmann, Alexander M. Dohnal, Bernhard Kuster, Susanna Skalicky
Publikováno v:
NPJ Vaccines
npj Vaccines, Vol 5, Iss 1, Pp 1-13 (2020)
npj Vaccines, Vol 5, Iss 1, Pp 1-13 (2020)
Glioblastoma is the most prevalent and aggressive brain cancer. With a median overall survival of ~15–20 months under standard therapy, novel treatment approaches are desperately needed. A recent phase II clinical trial with a personalized immunoth
Autor:
Thomas Felzmann
Dr. Max Thoma ist sehr beunruhigt, als er bei der an Krebs erkrankten, ehemaligen Escort Lady ‚Sabrina'die gleiche Anomalie entdeckt, die ihm zuvor schon bei einer jugendlichen Leukämie-Patientin Kopfzerbrechen bereitete, denn die Tumore bestehen
Autor:
Sol Efroni, Johannes A. Hainfellner, Alexander M. Dohnal, Adelheid Wöhrer, Christine Marosi, Thomas Felzmann, René Reitermaier, Friedrich Erhart, Carmen Visus, Simone Klingenbrunner, Katrin Fischhuber, Gerda Ricken, Christine Haberler, Dror Hibsh, Renana Kozol, Günther Krumpl, Johanna Buchroithner, Ido Sloma
Publikováno v:
Acta Neuropathologica Communications
Acta Neuropathologica Communications, Vol 6, Iss 1, Pp 1-14 (2018)
Acta Neuropathologica Communications, Vol 6, Iss 1, Pp 1-14 (2018)
Audencel is a dendritic cell (DC)-based cellular cancer immunotherapy against glioblastoma multiforme (GBM). It is characterized by loading of DCs with autologous whole tumor lysate and in vitro maturation via “danger signals”. The recent phase I
Autor:
Marie Le Bras, Thomas Felzmann, Angela Halfmann, Matthias Gaestel, Fiona Poyer, Klara Soukup, Thomas Haider, Sarah Vittori, Gernot Schabbauer, Emine Sahin, Stephan Blüml, Cornelia Schuh, Romana Luger, Alexey Kotlyarov, Birgit Niederreiter, Dagmar Stoiber, Alexander M. Dohnal
Publikováno v:
The Journal of Immunology. 195:541-552
Dendritic cell (DC)–mediated inflammation induced via TLRs is promoted by MAPK-activated protein kinase (MK)-2, a substrate of p38 MAPK. In this study we show an opposing role of MK2, by which it consolidates immune regulatory functions in DCs thro
Autor:
Neringa Dobrovolskiene, Daniel J. Powell, Marius Strioga, Virgil E.J.C. Schijns, Thomas Felzmann, Miroslava Matuskova, Valerijus Ostapenko, Jaroslav Michálek
Publikováno v:
Critical Reviews in Immunology, 33(6), 489-547
Critical Reviews in Immunology 33 (2013) 6
Critical Reviews in Immunology 33 (2013) 6
Dendritic cells (DCs) are the most potent professional antigen-presenting cells, capable of initiating proper adaptive immune responses. Although tumor-infiltrating DCs are able to recognize cancer cells and uptake tumor antigens, they often have imp
Autor:
Günther Stockhammer, Friedrich Erhart, Thomas Czech, Sarah Iglseder, Reinhard Ruckser, Martha Nowosielski, Christine Marosi, Carmen Visus, Matthias Preusser, Markus Hoffermann, Thomas Felzmann, Gord von Campe, Johanna Buchroithner, Karin Bordihn, Sabine Spiegl-Kreinecker, Christian F. Freyschlag, Karl Rössler, Michael B. Fischer, Günther Krumpl, Stefan Oberndorfer, Josef Pichler, Georg Widhalm
Publikováno v:
Cancers
Volume 10
Issue 10
Cancers, Vol 10, Iss 10, p 372 (2018)
Volume 10
Issue 10
Cancers, Vol 10, Iss 10, p 372 (2018)
Dendritic cells (DCs) are antigen-presenting cells that are capable of priming anti-tumor immune responses, thus serving as attractive tools to generate tumor vaccines. In this multicentric randomized open-label phase II study, we investigated the ef